RxDoctor Payments Data

John Caruso, DO

Family Medicine · Loysville, PANPI 1912946617

Payments from drug & device makers

$15,353in general payments, 2019–2025

Across 987 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • GSK$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$755
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$15,321100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,353 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$163,890
Medicare patients
367
Services billed
2,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin142$142,089
OzempicSemaglutide109$138,798
EliquisApixaban121$104,386
XareltoRivaroxaban58$62,878
MounjaroTirzepatide36$62,514
JanuviaSitagliptin Phosphate60$60,533
Synjardy XrEmpagliflozin/Metformin Hcl44$55,097
RybelsusSemaglutide23$40,956
FarxigaDapagliflozin Propanediol26$39,484
MyrbetriqMirabegron56$38,897
TradjentaLinagliptin36$31,964
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$24,392
TrulicityDulaglutide21$21,256
Tresiba Flextouch U-100Insulin Degludec24$19,249
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$16,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$1,124$229,150222 claims
Novo NordiskOzempic, Rybelsus$3,337$179,755132 claims
PfizerEliquis$721$104,386121 claims
Lilly USA, LLCMounjaro, Trulicity$755$83,77057 claims
Johnson & JohnsonXarelto$328$62,87858 claims
MerckJanuvia$416$60,53360 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,358$40,62755 claims
AstraZenecaFarxiga$1,337$39,48426 claims
Astellas Pharma US IncMyrbetriq$58$38,89756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Loysville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →